Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Takeda Pharmaceutical Company Ltd. Under the terms of the agreement, Adimab will use its proprietary platform to discover and
optimize antibodies against multiple targets chosen by Takeda, who will have the right to develop and commercialize therapeutic programs resulting from the
collaboration.

Read More